Pharmacists were instructed to ask each person dropping off or picking up a prescription about concurrent NHP-drug use, and the occurrence of any potential AE. Telephone interviews conducted by a study team member were used to follow up if an AE was reported. Up to three months of active surveillance was planned in ten community pharmacies in Ontario. All cases were independently adjudicated for causality, seriousness and outcome by 2 study team members with expertise in NHPs. Algorithms used for adjudication included the WHO guidelines, Naranjo causality scale, and Horn algorithm (drug interaction probability scale). RESULTS: Over 2000 patients have been screened. A total of 759 reported taking NHPs and drugs concurrently, 35 were identified as having suspected AEs, and 15 consented to, and were available for, an in-depth interview. Two not previously described probable NHP-drug interactions have been identified including analysis of their purported CYP450 pharmacokinetic mechanisms. In case 1, strong sedation occurred after concomitant intake of citalopram, nortriptyline, oxycodone, and melatonin. Melatonin was shown to inhibit CYP2C19 and thus citalopram metabolism. In case 2, heart palpitations occurred after concomitant intake of two NHPs containing a variety of active substances and progesterone cream use. Laboratory analyses to investigate possible mechanisms to explain the clinical symptoms described is ongoing. CONCLUSIONS: In this study, the rate of AEs suspected to be related to NHP use was 5.7%. Active surveillance of NHP-drug interactions and NHP-related AEs in community pharmacies is feasible and provides an effective way to discover unknown pharmacokinetic and pharmacodynamic NHP-related interactions. Along with neutropenia and anemia, thrombocytopenia is one of the most common hematological complications of cancer treatment. Prolonged/severe thrombocytopenia increases the risk of bleeding. The goal of this study was to evaluate the epidemiology of thrombocytopenia among cancer patients on chemotherapy. METHODS: Data were collected between 2000-2007 from a large electronic medical records database in 18 outpatient oncology clinics throughout the US. Adult patients with NSCLC, breast, ovarian, H&N, and colorectal cancers were of interest. Chemotherapy regimens were grouped into platinum-, anthracycline-, gemcitabine-, and taxane-based. Thrombocytopenia ( 150,000 l) prevalence was examined by tumor and regimen type. RESULTS: A total of 47,159 patients [mean age 61, male 42%] and 75,243 chemotherapy regimens were analyzed. Breast cancer patients constituted 19.5%, followed by NSCLC (14.9%), colorectal (11.9%), ovarian (3.1%), and H&N (2.5%). Platinum-based regimens accounted for 27.8% of all regimens. Prevalence of post-chemo thrombocytopenia was highest among gemcitabine treated patients (64.2%), followed by platinum (55.5%), and lowest with taxane-based regimens (21.9%). Most of the patients across all treatment regimen groups presented with thrombocytopenia (grade 1). Eleven percent of patients on platinum and gemcitabine regimens, 2% in taxane-treated patients, and 5% in anthracycline-treated patients had PC 50 10 9 /L (grade 3-4). Patients with NSCLC and ovarian cancer had the highest incidence of thrombocytopenia. A substantial proportion of patients, 30% developed both anemia and thrombocytopenia after chemotherapy start. More than 90% of patients with thrombocytopenia grade 1-3 also had anemia grade 1 or 2. Twenty percent of those with grade 4 thrombocytopenia presented with anemia grade 3-4. Of these, 16.7% had NSCLC, 16.2% were breast cancer patients, and 9.1% were colorectal cancer patients. Platelet transfusions were rare ( 5% of all chemotherapy-treated patients). CONCLUSIONS: Thrombocytopenia was common in this large cohort of cancer patients on chemotherapy. A substantial proportion of patients developed both anemia and thrombocytopenia. Cancer patients receiving chemotherapy may often require chemotherapy dose delays and dose reductions due to chemotherapy-induced side effects such as thrombocytopenia, neutropenia, and anemia. In responsive cancers, such dose delay and dose reduction of chemotherapy may be associated with decreased effectiveness and poorer clinical outcomes. In this study, we analyzed the characteristics of dose delay among cancer patients on chemotherapy. METHODS: Data from 2000-2007 from a large electronic database of outpatient oncology clinics in the US were analyzed. Adult patients with a cancer diagnosis and complete chemotherapy plan information were eligible for this analysis. Chemotherapies were grouped into platinum-, anthracycline-, gemcitabine-, taxane-based, and other. The planned cycle duration was compared to the actual duration. A difference of more than 7 days was defined as a cycle delay. RESULTS: The dataset included 47,159 cancer patients (mean age 61 (SD 13), male 42%) and 75,243 chemotherapy regimens. A total of 26,317 patients (113,175 chemo cycles) had complete chemotherapy plan information. Of these, 5961 (22.7%) experienced chemo delays in 9293 cycles (8%) during chemotherapy. The average length of delay was 17 days (SD, 8 days; median, 14 days); 25% of the delays were more than 3 weeks. Tumor types of the 5,961 patients with cycle delays included, colorectal cancer (20.3%), NSCLC (18.6%), breast cancer (15.2%), ovarian (4.4%), and H&N (2.9%). The reasons for delaying chemo were not specified in the database. However, many (60%) experienced anemia (Hb 11 g/dL) or thrombocytopenia ( 150,000 l, 62%) at some point during chemotherapy. CONCLU-SIONS: Chemotherapy cycle delays were relatively common in this large group of cancer patients. While decisions to delay therapy were multi-factorial, further research is needed to investigate the reasons, preventable measures, clinical and cost outcomes of these delays.
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PCN2 DOSE DELAY AMONGST CANCER PATIENTS UNDERGOING CHEMOTHERAPY

PCN3 HEAD AND NECK CANCER PATIENTS AT INCREASED RISK OF COMORBIDITY COMPARED TO CANCER-FREE CONTROLS
van Herk-Sukel MPP 1 , Landis SH 2 , van den Haak P 1 , Janssen-Heijnen ML 3 , El-Hariry IA 2 , Penning-van Beest FJA 1 , Herings RM 1 1 PHARMO Institute, Utrecht, Utrecht, The Netherlands, 2 GlaxoSmithKline, Greenford, UK, 3 Eindhoven Cancer Registry, Eindhoven, The Netherlands OBJECTIVES: As comorbidity has a direct impact on choice of cancer treatment and patient prognosis after diagnosis, this study compared the prevalence and incidence of comorbidity among head and neck cancer (HNC) patients to a cancer-free population in the Netherlands. METHODS: Patients diagnosed with oral cavity, pharynx (excluding nasopharynx), and larynx cancer between 2000-2006 were selected from the PHARMO RLS and Eindhoven Cancer Registry. Each HNC patient was matched by age and gender to four cancer-free controls selected from the PHARMO RLS with date of cancer diagnosis selected as the index date for both cohorts. Comorbidities including diabetes, cardiovascular disease (CVD), anaemia, asthma/COPD, pneumonia, and depression were identified by prescription and/or hospitalisation data. Prevalence ratios and hazard ratios (HRs) were used to compare the occurence of events before and after diagnosis, respectively. RESULTS: Patients diagnosed with oral cavity, pharynx (excluding nasopharynx), and larynx cancer between 2000-2006 were selected from the PHARMO RLS and Eindhoven Cancer Registry. Each HNC patient was matched by age and gender to four cancer-free controls selected from the PHARMO RLS with date of cancer diagnosis selected as the index date for both cohorts. Comorbidities including diabetes, cardiovascular disease (CVD), anaemia, asthma/COPD, pneumonia, and depression were identified by prescription and/or hospitalisation data. Prevalence ratios and hazard ratios (HRs) were used to compare the occurence of events before and after diagnosis, respectively. CONCLUSIONS: HNC patients suffer from significantly higher prevalence and incidence of both chronic and acute comorbidies, compared to cancer-free controls. These conditions may affect patient eligibity for aggressive treatment and place them at higher mortality risk.
PCN4 BISPHOSPHONATES AND TIME TO OSTEONECROSIS DEVELOPMENT.
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